LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Hand-Held Hemoglobin Analyzer with Secure POC Connectivity Enables Hematocrit Calculation

By LabMedica International staff writers
Posted on 19 Oct 2022
Image: DiaSpect Tm POC hemoglobin analyzer is now powered by EKF Link digital connectivity solution (Photo courtesy of EKF Diagnostics)
Image: DiaSpect Tm POC hemoglobin analyzer is now powered by EKF Link digital connectivity solution (Photo courtesy of EKF Diagnostics)

DiaSpect Tm, the hand-held hemoglobin analyzer from EKF Diagnostics (Penarth, Cardiff, UK), now connects securely to EKF Link, the company’s own point-of-care (POC) middleware, enabling additional features including a calculated hematocrit value and data management.

The DiaSpect Tm is a palm-sized, lightweight, robust and easily transportable POC hemoglobin analyzer that can be used in any screening setting, even in challenging climatic environments. This is because its reagent-less microcuvettes have up to 2.5 years shelf life, even after opening, and are unaffected by temperature and humidity. Its ‘always-on’ technology enables professionals to start using the device immediately; and the rechargeable internal battery, which provides up to 40 days/10,000 tests continuous use, offers the flexibility of not needing a power source for weeks at a time. The enhanced DiaSpect Tm can now be connected to the recently released EKF Link middleware, ensuring that test results are stored and accessed securely on a centralized platform. EKF’s DiaSpect Tm is also now equipped with Bluetooth, internal storage for 4000 tests and QC results, as well as the capability to provide a calculated hematocrit value alongside the usual hemoglobin result.

Moving into a new era of POC connectivity, the DiaSpect Tm results are easily accessible from a web browser through EKF Link while being securely protected on the servers already available in most laboratories and hospitals. Patient and operator identification allow for better tracking of both staff competence and test results, and a Quality Control reminder function ensures compliance with ever tightening local regulations. Enabling rapid decision making, the DiaSpect Tm simultaneously delivers hemoglobin with calculated hematocrit results in under two seconds from just 10 µL of capillary or venous blood collected in microcuvettes and inserted directly into the analyzer. This makes it extremely user-friendly requiring minimal training. In addition, no calibration is required as it is factory calibrated against the HiCN reference method, and turbidity is also measured and compensated for. Available globally, the DiaSpect Tm has received an IVD CE-mark, FDA clearance and is registered in many more countries across all continents.

“Our new DiaSpect Tm will enable POC coordinators, operating rooms and screening programs to connect this fast and reliable photometric hemoglobin analyzer to Laboratory Information Systems (LIS) or Patient Information Systems (PIS) through EKF Link,” said David Wojahn, Hematology Product Manager for EKF Diagnostics. “Now with the EKF Link connectivity, DiaSpect Tm is an ideal POC solution enabling users to rapidly upload results from anywhere and power up their performance, delivering results directly alongside the patient or blood donor.”

Related Links:
EKF Diagnostics 

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more